

Bob Champion Cancer Trust

Unaudited

Trustees' Report and Financial Statements

For the year ended 30 June 2024

Bob Champion Cancer Trust

Contents

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 28

Bob Champion Cancer Trust

Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2024

Co-Founders

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)
Nicholas Embiricos (deceased November 2018)

President

Bob Champion, C.B.E.

Medical Advisor

Professor David Dearnaley

Vice Presidents

Clare Balding, C.B.E.
Willie Carson, O.B.E.
Kristina Cook
David Gower, O.B.E.
Chris Hughes
Jonjo O'Neill
Greg Rusedski
Peter Shilton, O.B.E.
Nick Skelton, C.B.E.

Trustees

Michael Cattermole (Chairman)
Susie Burrage, O.B.E.
Alex Embiricos
Timothy Fox
Andrew Franklin
Catherine McAleavey
Catherine Nash
Luke Ponsonby
Bridget Rosser
Carolyn Zetter Wells

Trust Officer

Mrs. Lucienne Wilkinson

Charity registered number

1024664

Principal Office

7 Square Rigger Row
Plantation Wharf
London
SW11 3TZ

Accountants

UHY Hacker Young
Chartered Accountants
Thames House
Roman Square
Sittingbourne
Kent ME10 4BJ

Bob Champion Cancer Trust

Trustees' report For the year ended 30 June 2024

The Trustees present their report and the accounts for the year ended 30 June 2024.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

Structure, Governance and Management

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

Background to the Trust

Bob Champion was one of the UK's top five jump jockeys when, in July 1979, he discovered he had cancer in two parts of his body and was given eight months to live. His doctors, at the Royal Marsden Hospital, suggested his only chance was a drastic new type of treatment, he readily agreed. The one thing that gave him the will to keep fighting during those gruelling months of treatment was the dream of riding Aldaniti in the Grand National.

In 1981, less than two years from diagnosis, that dream came true as Bob Champion and Aldaniti won the 1981 Grand National - racing's greatest fairytale. His victory led to the foundation in 1983 of the Bob Champion Cancer Trust.

The Trust's first project was to open its own Unit within the Royal Marsden Hospital, which was achieved five years, nearly to the day, after their Aintree victory. The Trust then concentrated on funding cancer research projects at the Institute of Cancer Research, opening in conjunction with the ICR in 2000, the first male dedicated cancer research facility in Europe – The Bob Champion Cancer Trust Research Centre. In 2015 The Bob Champion Research and Education Building was opened, a state-of-the-art research facility on the University of East Anglia campus costing, in excess, of £19 million.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2024

Objectives and Activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust, with The University of East Anglia (UEA), opened the Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments, not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases. This £19 million facility includes a unique bio-bank facility to store DNA and tissue samples plus teaching facilities suitable for training medical practitioners in rooms reflecting the functions of operational hospital bays.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, promotional mailings and active social media campaigns. The events range from themed event and parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon, and cycling events, these hopefully offer something for all our supporters and helps to attract new interest to the cause. An annual charity raceday at Plumpton Racecourse is held, now in its seventh year, which is an established and extremely popular fundraiser. During the day a Shetland Pony race is held as an extra attraction which helps raise further funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. A traditional church service is followed by a drinks party in the church hall attached and is very popular with the order of service raising extra funds from advertisers. The Trust is hoping to establish an annual golf tournament, two have been held so far with another planned for 2025 plus aims to hold a second raceday in the Spring.

The Trust is delighted to be continuing its involvement with the Shetland Pony Grand National (SPGN), now for the eighth year. The SPGN is a major part of the London International Horse Show held at the ExCel Exhibition Centre, with the SPGN grand finale a highlight of the four days. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show. The ten jockeys (aged between 9-14 years) once they qualify for the Show via the heats commit to raise a minimum of £1,000 sponsorship in support of the Trust, although, with determined future jockeys, nearly all participants way surpass this goal.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises vital funds but spreads awareness of the cause and the work of the Trust. The artist is selected each year and kindly donates their work and time in support of the Trust. In 2021 a second, smaller card, was added to create a choice for our supporters, again, double sided and kindly painted for us and donated by the artist. The larger card offers a more classic choice with the smaller card being more fun. The Trust has found that sales have suffered due to increased postage costs but the cards still represents an important part of the Trusts awareness message.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2024

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

Public Benefit

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

Achievements and performance

Each year 52,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

The Bob Champion Research Trust funded researchers have worked together as part of international consortium, called The Pan Prostate Cancer Group, set up by Professor Colin Cooper at The University of East Anglia (UEA) and Professor Ros Eeles the Institute of Cancer Research (ICR) to analyse genetic data from prostate cancer samples across nine countries.

Application of Artificial Intelligence to results obtained in the UK has helped scientists reveal two distinct forms of prostate cancer called Evotypes, with one being very aggressive prostate cancer. These results could revolutionise how the disease is diagnosed and managed, since it is important that treatment is targeted to aggressive disease. Crucially, the team aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.

The researchers used AI to study changes in the DNA of prostate cancer samples (using whole genome sequencing) from 159 patients. They identified two distinct cancer groups among these patients using an AI technique called neural networks. These two groups were confirmed by using two other mathematical approaches applied to different aspects of the data. This finding was validated in other independent datasets from Canada and Australia.

The work published in the Journal Cancer Genomics in 2024 was carried out in collaboration with Dr Dan Woodcock at the University of Oxford and Professor David Wedge at the University of Manchester who led the research. The team hope their findings could save thousands of lives in future and revolutionise how prostate cancer is diagnosed and treated. Ultimately, it could provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2024

Although prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. This means that unnecessary treatment can often be avoided, sparing men from side-effects such as incontinence and impotence.

These studies are important as until now, it was thought that prostate cancer was just one type of disease. But now, with advancements in artificial intelligence, the researchers have been able to show that there are actually two different subtypes at play.

Hopefully the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, and Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust, confirms that this study has utilised the enormous genomic dataset from The Pan Prostate Cancer Group which is a powerhouse of information about prostate cancer from around the world.

The Trust also supports Professor Ros Eeles with a three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The Information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

The Trust is in its final year of a three year grant for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator at the Bob Champion Unit, Royal Marsden Hospital, Sutton.

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patients experience of cancer treatment and subsequent quality of life.

Bob Champion Cancer Trust

Trustees' report (continued)
For the year ended 30 June 2024

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao focusses particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

Key trials in long term follow-up:

- **The IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer. The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- **The CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- **The PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

Publications:-**Genomic evolution shapes prostate cancer disease type.**

Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentre SC, Farmery JHR; CRUK ICGC Prostate Group; Van Loo P, Warren AY, Gnanapragasam V, Hamdy FC, Bova GS, Foster CS, Neal DE, Lu YJ, Kote-Jarai Z, Fraser M, Bristow RG, Boutros PC, Costello AJ, Corcoran NM, Hovens CM, Massie CE, Lynch AG, Brewer DS, Eeles RA, Cooper CS, Wedge DC. Cell Genom. 2024 ;4(3):100511. doi: 10.1016/j.xgen.2024.100511.

Bob Champion Cancer Trust

Trustees' report (continued) For the year ended 30 June 2024

Cancer invasion and anaerobic bacteria: new insights into mechanisms.

Hurst R, Brewer DS, Gihawi A, Wain J, Cooper CS. J Med Microbiol. 2024;73(3):001817. doi: 10.1099/jmm.0.001817.

Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.

Smith SF, Brewer DS, Hurst R, Cooper CS. Cancers (Basel). 2024 ;16(9):1717. doi: 10.3390/cancers16091717.

Major data analysis errors invalidate cancer microbiome findings.

Gihawi A, Ge Y, Lu J, Puiu D, Xu A, Cooper CS, Brewer DS, Pertea M, Salzberg SL. mBio. 2023;14(5):e0160723. doi: 10.1128/mbio.01607-23.

Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer.

Yazbek Hanna M, Winterbone M, O'Connell SP, Olivan M, Hurst R, Mills R, Cooper CS, Brewer DS, Clark J. Cancers (Basel). 2023 ;15(3):789. doi: 10.3390/cancers15030789.

There are currently 11 papers under review.

Financial Review

The Trust incurred an overall surplus for the year of £332,459 (2023: deficit of £44,860). The surplus for the year was given a significant boost by a generous legacy received in the year totalling £199,735 (2023: £1,393). Also included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £184,412 (2023: £71,655) and dividends received of £46,708 (2022: £46,366). In addition, the unrealised gain on investments for the year to 30 June 2024 was £112,344 (202: £54,724).

The Trustees are satisfied that the Trust's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the Trust to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

Bob Champion Cancer Trust

**Trustees' report (continued)
For the year ended 30 June 2024**

Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at the Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

Approval

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:
Michael Cattermole
D17B32C730044CE...

Michael Cattermole
Trustee

DocuSigned by:
Luke Ponsonby
079866F1D2FD4CA...

Luke Ponsonby
Trustee

Date: 23 April 2025

Bob Champion Cancer Trust

Statement of Trustees' responsibilities For the year ended 30 June 2024

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:

D17B32C730044CE...

Michael Cattermole

Trustee

Date: 23 April 2025

Bob Champion Cancer Trust

Independent Examiner's Report For the year ended 30 June 2024

Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2024.

Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants England and Wales, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:  Signed by:
1102ED52BDD84BD...

Dated: 24 April 2025

Tracey Moore BFP ACA

UHY Hacker Young

Chartered Accountants

Bob Champion Cancer Trust

Statement of financial activities
For the year ended 30 June 2024

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
Income from:				
Donations and legacies	4	209,883	209,883	6,295
Other trading activities - Fundraising	5	359,344	359,344	177,711
Investments	6	46,708	46,708	46,366
Total income		<u>615,935</u>	<u>615,935</u>	<u>230,372</u>
Expenditure on:				
Raising funds	7	174,932	174,932	106,056
Charitable activities		220,888	220,888	223,900
Total expenditure		<u>395,820</u>	<u>395,820</u>	<u>329,956</u>
Net income/(expenditure) before net gains on investments		220,115	220,115	(99,584)
Net gains on investments		112,344	112,344	54,724
Net movement in funds		<u>332,459</u>	<u>332,459</u>	<u>(44,860)</u>
Reconciliation of funds:				
Total funds brought forward		1,528,851	1,528,851	1,573,711
Net movement in funds		332,459	332,459	(44,860)
Total funds carried forward		<u>1,861,310</u>	<u>1,861,310</u>	<u>1,528,851</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 28 form part of these financial statements.

Bob Champion Cancer Trust

Balance sheet
As at 30 June 2024

	Note	2024 £	2023 £
Fixed assets			
Tangible assets	13	1,571	1,119
Investments	14	1,693,539	1,506,195
		<u>1,695,110</u>	<u>1,507,314</u>
Current assets			
Debtors	15	1,861	4,282
Cash at bank and in hand		192,340	90,538
		<u>194,201</u>	<u>94,820</u>
Creditors: amounts falling due within one year	16	(28,001)	(73,283)
		<u>166,200</u>	<u>21,537</u>
Net current assets		<u>166,200</u>	<u>21,537</u>
Total net assets		<u><u>1,861,310</u></u>	<u><u>1,528,851</u></u>
Charity funds			
Unrestricted funds	18	1,861,310	1,528,851
Total funds		<u><u>1,861,310</u></u>	<u><u>1,528,851</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:

 D17B32C730044CE...

Michael Cattermole
 Trustee

Date: 23 April 2025

DocuSigned by:

 079866F1D2FD4CA...

Luke Ponsonby
 Trustee

The notes on pages 14 to 28 form part of these financial statements.

Bob Champion Cancer Trust

Statement of cash flows
For the year ended 30 June 2024

	Note	2024 £	2023 £
Cash flows from operating activities			
Net cash used in operating activities	20	131,029	(141,381)
Cash flows from investing activities			
Dividends, interests and rents from investments		46,708	46,366
Purchase of property, plant and equipment		(935)	-
Proceeds from sale of investments		-	125,000
Purchase of investments		(75,000)	-
Net cash (used in)/provided by investing activities		(29,227)	171,366
Change in cash and cash equivalents in the year		101,802	29,985
Cash and cash equivalents at the beginning of the year		90,538	60,553
Cash and cash equivalents at the end of the year	21	192,340	90,538

The notes on pages 14 to 28 form part of these financial statements

Bob Champion Cancer Trust

Notes to the financial statements For the year ended 30 June 2024

1. General information

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

2. Accounting policies

2.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

2.2 Basis of non-consolidation

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

2.3 Going concern

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

2. Accounting policies (continued)**2.4 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

2.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

2. Accounting policies (continued)**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

2.7 Tangible fixed assets and depreciation

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings	-	20% reducing balance
Computer equipment	-	25% reducing balance

2.8 Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

2.9 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

2.10 Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

2. Accounting policies (continued)**2.11 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

2.12 Financial instruments

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

2.13 Pensions

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

2.14 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

3. Critical accounting estimates and areas of judgment

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

4. Income from donations and legacies

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Donations	10,148	10,148	4,902
Legacies	199,735	199,735	1,393
Total 2024	<u>209,883</u>	<u>209,883</u>	<u>6,295</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

5. Income from other trading activities - fundraising
Income from fundraising events

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
General Fundraising	35,528	35,528	23,787
Christmas Season	30,046	30,046	12,670
Carols and Champagne	60,918	60,918	-
Shetland Pony Grand National	12,000	12,000	30,012
Plumpton Raceday	122,749	122,749	111,242
Wincanton Raceday	98,103	98,103	-
Total 2024	<u>359,344</u>	<u>359,344</u>	<u>177,711</u>

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

6. Investment income

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Listed securities	43,799	43,799	46,293
Bank deposits	2,909	2,909	73
Total 2024	<u>46,708</u>	<u>46,708</u>	<u>46,366</u>

In both the current and prior year all income from investments was in relation to unrestricted funds.

7. Expenditure on raising funds
Publicity and fundraising expenses

	Unrestricted funds 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
General Fundraising costs	14,340	14,340	6,724
Christmas Season	13,780	13,780	11,284
Carols and Champagne	14,753	14,753	-
Shetland Pony Grand National	952	952	819
Plumpton Raceday	46,104	46,104	44,554
Wincanton Raceday	41,341	41,341	-
Publicity and direct administrative costs	43,662	43,662	42,675
	<u>174,932</u>	<u>174,932</u>	<u>106,056</u>
<i>Total 2023</i>	<u>106,056</u>	<u>106,056</u>	

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

8. Research Grants

	Grants to Institutions 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	84,998	84,998	72,574
Professor Colin Cooper grant - UEA	13,588	13,588	31,317
Clinician Annie Gao	31,543	31,543	31,543
Total 2024	<u>130,129</u>	<u>130,129</u>	<u>135,434</u>

Professor Ros Eeles, Prostate Cancer Sequencing Germline DNA Project at the ICR, to predict who will develop aggressive or lethal prostate cancer commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19 delays the grant ended, and was then extended for a further three years in October 2023 at the cost of £349,294.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded initially in January 2020 for two years at a cost of £80,000. The BCCT continued to fund this project with Rachel Hurst with funds being taken up to, but no later, than 31 December 2024. The BCCT will pay 75% of the total grant, approximately £50,000 per annum.

Dan Brewer within Professor Colin Cooper's team on the DESNT project this grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

Furthermore, in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, ICR/Royal Marsden Hospital. The agreed funding for £42,000 per year is for 3 years (including standard on-costs) commencing from 1 September 2021.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,693,539 that can be turned into cash as required.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

9. Charitable expenditure

	Grant funding of activities 2024 £	Support costs 2024 £	Total funds 2024 £	<i>Total funds 2023 £</i>
Grants to institutions (note 8)	130,129	-	130,129	135,434
Staff costs	-	63,360	63,360	59,337
Depreciation	-	483	483	641
Premises costs	-	5,755	5,755	3,737
Travel costs	-	1,041	1,041	744
Computer and IT costs	-	3,049	3,049	4,174
General office costs	-	7,650	7,650	7,924
Governance costs	-	9,421	9,421	11,909
	<u>130,129</u>	<u>90,759</u>	<u>220,888</u>	<u>223,900</u>
<i>Total 2023</i>	<u>135,434</u>	<u>88,466</u>	<u>223,900</u>	

Governance costs comprise Trustees' indemnity insurance and independent examiner's fees (2023: Trustees' indemnity insurance, legal fees and independent examiner's fees).

10. Independent examiner's remuneration

	2024 £	<i>2023 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,100</u>	<u>4,950</u>

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

11. Staff costs

	2024	<i>2023</i>
	£	£
Wages and salaries	60,000	56,000
Social security costs	1,618	1,657
Contribution to defined contribution pension schemes	1,742	1,680
	<u>63,360</u>	<u>59,337</u>

The average number of persons employed by the Charity during the year was as follows:

	2024	<i>2023</i>
	No.	No.
Employees	<u>1</u>	<u>1</u>

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel comprise of the Trustees and the Executive Director. Total employment benefits (including social security contributions and employers' pension contributions) of key management personnel during the year were £63,422 (*2023: £59,337*).

12. Trustees' remuneration and expenses

During the year, no Trustees received any remuneration or other benefits (*2023 - £NIL*).

During the year, donations given by trustees totalled £1,698 (*2023: £Nil*).

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

13. Tangible fixed assets

	Fixtures and fittings £	Office equipment £	Total £
Cost			
At 1 July 2023	-	6,782	6,782
Additions	118	817	935
At 30 June 2024	<u>118</u>	<u>7,599</u>	<u>7,717</u>
Depreciation			
At 1 July 2023	-	5,663	5,663
Charge for the year	24	459	483
At 30 June 2024	<u>24</u>	<u>6,122</u>	<u>6,146</u>
Net book value			
At 30 June 2024	<u>94</u>	<u>1,477</u>	<u>1,571</u>
At 30 June 2023	<u>-</u>	<u>1,119</u>	<u>1,119</u>

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

14. Fixed asset investments

	Investments in subsidiary companies £	Listed investments £	Total £
Cost or valuation			
At 1 July 2023	2	1,506,193	1,506,195
Additions	-	75,000	75,000
Revaluations	-	112,344	112,344
At 30 June 2024	2	1,693,537	1,693,539

At 30 June 2024, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,693,537 (2023: £1,506,193). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

Subsidiary undertakings

The following was a subsidiary undertaking of the Charity:

Name	Holding	Included in consolidation
Aldaniti Trading Company Limited	100%	No

The financial results of the subsidiary for the year were:

Name	Net assets £
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

15. Debtors

	2024 £	2023 £
Prepayments	1,861	4,282

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

16. Creditors: Amounts falling due within one year

	2024	2023
	£	£
Trade creditors	1,649	2,991
Amounts owed to group undertakings	2	2
Other taxation and social security	662	1,199
Other creditors	3,327	265
Accruals and deferred income	22,361	29,295
Grants committed	-	39,531
	<u>28,001</u>	<u>73,283</u>
	2024	2023
	£	£
Deferred income at 1 July 2023	12,975	-
Events income deferred during the year	8,967	12,975
Amounts released from previous periods	(12,975)	-
	<u>8,967</u>	<u>12,975</u>

17. Financial instruments

	2024	2023
	£	£
Financial assets		
Financial assets measured at fair value through income and expenditure	<u>1,693,537</u>	<u>1,506,193</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

Bob Champion Cancer Trust

Notes to the financial statements
For the year ended 30 June 2024

18. Statement of funds**Statement of funds - current year**

	Balance at 1 July 2023	Income	Expenditure	Gains/ (Losses)	Balance at 30 June 2024
	£	£	£	£	£
Unrestricted funds					
Reserves	1,528,851	615,935	(395,820)	112,344	1,861,310
	<u>1,528,851</u>	<u>615,935</u>	<u>(395,820)</u>	<u>112,344</u>	<u>1,861,310</u>

Statement of funds - prior year

	<i>Balance at 1 July 2022</i>	<i>Income</i>	<i>Expenditure</i>	<i>Gains/ (Losses)</i>	<i>Balance at 30 June 2023</i>
	£	£	£	£	£
Unrestricted funds					
Reserves	1,573,711	230,372	(329,956)	54,724	1,528,851
	<u>1,573,711</u>	<u>230,372</u>	<u>(329,956)</u>	<u>54,724</u>	<u>1,528,851</u>

19. Analysis of net assets between funds

	Unrestricted funds 2024	Total funds 2024	<i>Total funds 2023</i>
	£	£	£
Tangible fixed assets	1,571	1,571	1,119
Fixed asset investments heading	1,693,539	1,693,539	1,506,195
Current assets	194,201	194,201	94,820
Creditors due within one year	(28,001)	(28,001)	(73,283)
	<u>1,861,310</u>	<u>1,861,310</u>	<u>1,528,851</u>

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

20. Reconciliation of net movement in funds to net cash flow from operating activities

	2024 £	2023 £
Net income/expenditure for the period (as per Statement of Financial Activities)	332,459	(44,860)
Adjustments for:		
Depreciation charges	483	720
Losses on investments	(112,344)	(54,724)
Dividends, interests and rents from investments	(46,708)	(46,366)
Decrease/(increase) in debtors	2,421	(4,008)
Increase/(decrease) in creditors	(45,282)	7,857
Net cash provided by/(used in) operating activities	131,029	(141,381)

21. Analysis of cash and cash equivalents

	2024 £	2023 £
Cash in hand	192,340	90,538
Total cash and cash equivalents	192,340	90,538

22. Analysis of changes in net debt

	At 1 July 2023 £	Cash flows £	At 30 June 2024 £
Cash at bank and in hand	90,538	101,802	192,340
	90,538	101,802	192,340

23. Pension commitments

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,680 (2023: £1,680). Contributions totaling £327 (2023: £265) were payable to the fund at the balance sheet date and are included in creditors.

Bob Champion Cancer Trust

**Notes to the financial statements
For the year ended 30 June 2024**

24. Related party transactions

During the year, the charity paid £29,387 (2023: £29,879) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,274 (2023: £7,479). Bob Champion's retainer has been approved by the Charity Commission.